Fortis Healthcare to divest Fortis Malar Hospital, Chennai to MGM Healthcare

The divestment is a part of Fortis' ongoing portfolio rationalization strategy

GSK announces positive results from DREAMM-7 head-to-head phase III trial for Blenrep

Blenrep (belantamab mafodotin) plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex

DxVx plans to make a license-in agreement of OVM-200

Final stage in licensing OVM-200 from Oxford Vacmedix in the UK

Lupin receives tentative approval from USFDA for Canagliflozin Tablets

Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor

Lupin receives approval from USFDA for Bromfenac Ophthalmic Solution

Bromfenac Ophthalmic Solution, 0.07% is indicated for the treatment of postoperative inflammation and reduction of ocular pain

Merck to acquire Caraway Therapeutics

Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases

Fosun Pharma USA and Treehill Partners to invest in biopharma space

The newly established business will be looking for high-quality, mid- to late-stage assets, clinically focused on the United States market

Evive Biotech and Acrotech Biopharma receive FDA approval of Ryzneuta

Lupin receives tentative approval from USFDA for Dapagliflozin Tablets

Dapagliflozin Tablets (RLD Farxiga) had estimated annual sales of USD 7282 million in the US

Lupin receives approval from USFDA for Pitavastatin Tablets

Pitavastatin Tablets are indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol